Homepage
Author:
Avidity Biosciences, Inc.
Posted Date:
February 26, 2026
Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Avidity Biosciences, Inc.
February 26, 2026
Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders
Avidity Biosciences, Inc.
February 23, 2026
The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1
Avidity Biosciences, Inc.
February 18, 2026
Avidity Biosciences Announces Expected Record Date for Spin-Off
Avidity Biosciences, Inc.
February 2, 2026
